EMEA gives details of Lunivia withdrawal
This article was originally published in Scrip
Sepracor withdrew its EU marketing authorisation application for Lunivia (eszopiclone) 2mg and 3mg tablets in May because the CHMP advised that the product could not be treated as a new active substance (scripnews.com, May 19th, 2009).
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.